Analysis: Accent Microcell Limited

NSE:ACCENTMIC Pharma - Formulators Market cap: ₹1.4K cr

Why is Accent Microcell Limited stock rising?

unit 3 phase 1 to generate 150 crores revenue at peak capacity by fy27
unit 3 phase 2 to achieve 75-80% capacity utilization from first year of operation starting march 2027
2400 metric ton fungible capacity for ccs production in unit 3 phase 1 by june 2026
india's first pulp-based cmc production to achieve export prices of 800-900 rupees per kg
unit 3 phase 1 to achieve 650-700 rupees per kg average realization for premium products by june 2026

Research report

companyname: Accent Microcell Limited ticker: ACCENTMIC sector: Pharmaceutical Excipients / Specialty Chemicals (Microcrystalline Cellulose and cellulose-based excipients) Accent Microcell makes microcrystalline cellulose (MCC) and cellulose-based excipients, the inactive ingredients that bind, fill, disintegrate and lubricate tablets and capsules. Every oral solid dose contains an active pharmaceutical ingredient and a matrix of excipients around it. Accent supplies that matrix. The company st...

Read the full report →

Growth guidance

FY27 revenue guided at ~800 crores driven by Phase 1 of Unit 3 commercialization

Guidance maintained

RS rating: 91 Stage: Stage 2

Get valuation models, detailed research reports, thematic primers, one-pagers, risk analysis, growth triggers, bear case, capex tracker, walk the talk, and more for Accent Microcell Limited and 4,900+ companies.

5-day free pass. No card required.